Are dementia and depression in Parkinson's disease related?

Lieberman, Abraham

doi:10.1016/j.jns.2006.05.022

Cited by 42 publications

(45 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high levels of neuropsychiatric disturbances from our patients with depression (NPI ¼ 24.9) and dementia (NPI ¼ 39.6) are in agreement with a previous study by Reading et al (2001) who proposed that scores around 20 or more are clinically significant. In the dementia group considered alone, our results could be compared with those reported by Lieberman (2006), which using the NPI in PD, found higher neuropsychiatric symptoms among demented than non-demented patients. On the other hand, while Aarsland et al (2007) found apathy as a more prominent domain, we found a spectrum composed by several relevant domains, as delusions, hallucinations, agitation, sleep disturbances, appetite changes and aberrant motor behaviour, as well, depressive symptoms.…”

Section: Resultssupporting

confidence: 53%

Psychopathological features in patients with Parkinson's disease and related caregivers' burden

Stella

Banzato

Quagliato

et al. 2009

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 53%

Psychopathological features in patients with Parkinson's disease and related caregivers' burden

Stella

Banzato

Quagliato

et al. 2009

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…Depressive symptoms may occur from the early stages and condition to a large extent the activities of daily living [28]. Depression has been associated with cognitive deterioration, especially when apathy is present [7,17]. The MMSE score has not proved to be a predictive factor for QoL.…”

Section: Discussionmentioning

confidence: 99%

Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease

et al. 2010

View full text Add to dashboard Cite

The objective of this study is to assess how the non-motor symptoms of Parkinson's disease (PD), such as depression, cognitive deterioration, neuropsychiatric and sleep disorders, affect the quality of life, and to compare them with the motor symptoms in order to determine their real impact. A cross-sectional study was designed including 99 patients (mean age 68.5 ± 9.9 years, duration of disease 8.7 ± 6.2 years). Demographic data, onset of PD, years on treatment with levodopa (LD), class of dopaminergic drug prescribed, and dosages were obtained. The following scales were used: quality of life (PDQ-39), Unified Parkinson's Disease Rating Scale (UPDRS I-IV), Parkinson Disease Sleep Scale (PDSS) and daytime sleepiness (Epworth), Mini-Mental State Examination, depression (HAM-D), and the neuropsychiatric inventory (NPI-10). The PDQ-39 summary index (PDQ-39 SI) was 24.7 ± 13.2. A linear regression model including all variables showed that four independent variables accounted for 67.2% of the variance in the PDQ-39 SI (F = 33,277; p < 0.001): NPI, PDSS, UPDRS IV, and UPDRS I. When sub-items of the NPI, PDSS and UPDRS IV scales are analyzed, significant correlations (p < 0.001) are found between the PDQ-39 SI and depression, agitation, apathy, anxiety, hallucinations, delusions, incontinence of urine, morning painful posturing, restlessness in bed, morning fatigue, duration of off periods, unpredictable and predictable off periods, early morning dystonia, and sudden off periods. Neuropsychiatric symptoms, especially depression, nighttime sleep disorders such as urinary incontinence, nighttime restlessness, morning fatigue and somnolence, off-period dystonia and motor fluctuations are the variables that most affect the quality of life of patients with PD.

show abstract

“…Besides the mesocorticolimibic dopaminergic system and its prominent role in affective states, disruptions of the dopaminergic system originating from the substantia nigra with projections to the basal ganglia (nigrostriatal dopaminergic system) result in deficits of motor functions, which are often co-morbid with or preceded by depressive disorders [41,42] , and which are also key symptoms in neurodegenerative neurological diseases, such as Parkinson's or Huntington's disease. Since we found an enhanced extracellular release of DA in the striatum upon intra-nasal application of DA [12] , we expected also to find psychostimulant effects of such application.…”

Section: Introductionmentioning

confidence: 99%

Behavioral Actions of Intranasal Application of Dopamine: Effects on Forced Swimming, Elevated Plus-Maze and Open Field Parameters

et al. 2008

View full text Add to dashboard Cite

Background: Recently, we found evidence that intra-nasally administered dopamine (DA), can enter the brain, leading to an immediate increase in extracellular DA levels in striatal subregions. This offers a potential alternative approach to target the brain with exogenous DA, which otherwise cannot cross the blood-brain barrier. Here, we examined whether intra-nasally applied DA also exerts behavioral activity on mesocortical and nigrostriatal dopaminergic functions. Method: Male Wistar rats (3–4 months) were tested for potential behavioral effects of intra-nasally applied DA (0.03, 0.3 or 3.0 mg/kg) in the forced swimming test (FST) for antidepressant-like activity, elevated plus-maze for anxiety-related behavior, and on motor activity in a novel and familiar environment. Results: Intra-nasally administered dopamine in a dose of 0.3 mg/kg exerted antidepressant-like activity in the FST, but had neither anxiolytic-like nor anxiogenic-like effects in the elevated plus-maze. Furthermore, intra-nasal dopamine stimulated locomotor activity in a familiar, but not novel, open field. Conclusions: These results support the view that intra-nasally applied DA can act on the central nervous system by entering the brain via the nose-brain pathway, making this kind of application procedure a promising alternative for targeting the brain, and thus treating disorders involving mesocortical and/or nigrostriatal dopaminergic disturbances.

show abstract

Are dementia and depression in Parkinson's disease related?

Cited by 42 publications

References 45 publications

Psychopathological features in patients with Parkinson's disease and related caregivers' burden

Psychopathological features in patients with Parkinson's disease and related caregivers' burden

Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease

Behavioral Actions of Intranasal Application of Dopamine: Effects on Forced Swimming, Elevated Plus-Maze and Open Field Parameters

Contact Info

Product

Resources

About